Legal
1. This week’s factual summary
For the week ending August 23, 2026, monitoring covered 20 distinct questions and 140 responses: 10 brand-focused questions and 10 product-information questions. The responses included 120 hedging/disclaimer tags, 87 infection-risk tags, 40 IBD tags, 33 overclaim-language tags, and 11 generic/biosimilar tags. The dataset records 26 cross-response inconsistency flags.
2. Trademark / brand-name usage patterns
Responses generally used “Cosentyx” as the named product and paired it with “secukinumab,” such as: “Cosentyx (secukinumab) is a biologic” and “Cosentyx targets IL-17A.”
One recurring usage pattern blends the brand with the active ingredient or therapeutic class. In switching responses, the text describes moving from “another IL-17 biologic” including “secukinumab” to Cosentyx (secukinumab), while also stating that the medicines may be “very similar.” Other responses refer to Cosentyx as an “IL-17A inhibitor” or “biologic,” rather than consistently distinguishing the branded product from the broader category.
3. Compounding, generic, and biosimilar language
The dataset contains 11 biosimilar/generic tags, up from 9 the prior week. No compounding-specific tally or excerpt was provided.
All seven responses to the pharmacy-substitution question addressed generic or biosimilar terminology. Common language included: “not usually substituted with a classic small-molecule generic,” “substitution—when allowed—typically involves a biosimilar,” and “what ‘substitution’ means depends on…insurance/pharmacy rules.” One response stated that “biosimilars to secukinumab” may be available. The responses did not identify a specific biosimilar product.
4. Language involving named competitors
Tagged superiority or comparative terms appeared alongside named competitors as follows:
- Taltz: 8 response variants, including “best,” “stronger,” and “superior.”
- Enbrel: 8, including repeated use of “stronger” and, in one response, “best.”
- Humira: 4, including “best.”
- Stelara: 3, including “best,” “leading,” or “stronger.”
- Skyrizi, Tremfya, and Rinvoq: 1 each, in a response using “stronger.”
The responses often advised neutral framing, including “neither is simply ‘stronger’” and avoiding language that ranks one product.
5. Trend across weeks
Compared with August 16, total responses increased from 120 to 140, while questions remained at 20. Inconsistency flags increased from 24 to 26. Biosimilar/generic tags rose from 9 to 11; overclaim language rose from 28 to 33; and competitor mentions increased for Humira (9 to 18) and Enbrel (8 to 17). These patterns recur across the available weeks.
6. Flagged for attorney review
- Competitor comparisons: “stronger,” “best,” and “superior” appeared with multiple named competitors.
- Substitution terminology: 11 biosimilar/generic tags and repeated pharmacy-substitution language.
- Brand/ingredient usage: some responses move between Cosentyx, secukinumab, and the IL-17 category.
- Cross-response variation: 26 inconsistency flags, including differences involving safety topics and dosing schedules.